Biotech startup Myonexus raises funds for clinical trial of muscular-dystrophy gene therapy

Biotechnology company Myonexus Therapeutics has raised $2.5 million in financing from CincyTech, Rev1 Ventures, the Jain Foundation and GFB ONLUS, which joined existing investors in the round of funding.

Myonexus launched in June as a spinout from the Research Institute at Nationwide Children’s Hospital.

The financing will enable Myonexus to begin the next phase of a clinical trial of the company’s gene therapy for treating limb-girdle muscular dystrophy.

There are more than 30 kinds of limb-girdle muscular dystrophy, and they vary in symptoms and severity. The condition begins in late childhood or early adulthood and causes weakness in the muscles around the hips and shoulders. The ability to walk is usually lost about 20 years after onset.

The latest round of funding will help bring Myonexus’ gene therapy a step closer to the market.